Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWP-101 in Advanced Solid Tumors
NCT04871347Phase 1Unknown
- Sponsor
- Therawisdom Biopharma
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sytalizumab in solid tumor (advanced stage), sponsored by Therawisdom Biopharma. Primary endpoints: Incidence of Dose-Limiting Toxicity at 4 weeks and Incidence of Adverse Events and Serious Adverse Events. Status: unknown.
02
Drugs
sytalizumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04871347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04871347.